


INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁵ : A61B 17/12	A1	(11) International Publication Number: WO 90/14796 (43) International Publication Date: 13 December 1990 (13.12.90)
<p>(21) International Application Number: PCT/NL90/00078</p> <p>(22) International Filing Date: 29 May 1990 (29.05.90)</p> <p>(30) Priority data: 8901350 29 May 1989 (29.05.89) NL</p> <p>(71)(72) Applicants and Inventors: MUIJS VAN DE MOER, Wouter, Matthijs [NL/NL]; Grindweg 56, NL-3055 VB Rotterdam (NL). RIENKS, Rienk [NL/NL]; Mennestraat 17, NL-3882 AN Putten (NL).</p> <p>(74) Agents: DE BRUIJN, Leendert, C. et al.; Nederlandsch Octrooibureau, Scheveningseweg 82, P.O. Box 29720, NL-2502 LS The Hague (NL).</p>		<p>(81) Designated States: AT, AT (European patent), AU, BB, BE (European patent), BF (OAPI patent), BG, BJ (OAPI patent), BR, CA, CF (OAPI patent), CG (OAPI patent), CH, CH (European patent), CM (OAPI patent), DE*, DE (European patent)*, DK, DK (European patent), ES, ES (European patent), FI, FR (European patent), GA (OAPI patent), GB, GB (European patent), HU, IT (European patent), JP, KP, KR, LK, LU, LU (European patent), MC, MG, ML (OAPI patent), MR (OAPI patent), MW, NL, NL (European patent), NO, RO, SD, SE, SE (European patent), SN (OAPI patent), SU, TD (OAPI patent), TG (OAPI patent), US.</p> <p>Published <i>With international search report. Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments. In English translation (filed in Dutch).</i></p>
<p>(54) Title: OCCLUSION ASSEMBLY FOR SEALING OPENINGS IN BLOOD VESSELS AND A METHOD FOR SEALING OPENINGS IN BLOOD VESSELS</p> <div data-bbox="378 1169 1304 1705" data-label="Image">  </div> <p>(57) Abstract</p> <p>Occlusion assembly for sealing openings in blood vessels (8) consisting of an occlusion element (13) and fixing element (12) to be fitted through the openings in the blood vessel. The fixing element is firmly connected to a retaining element (2). A locking element (10) engages on the retaining element. This locking element (10) is fitted horizontally against the outside of the blood vessel (8).</p>		

DESIGNATIONS OF "DE"

Until further notice, any designation of "DE" in any international application whose international filing date is prior to October 3, 1990, shall have effect in the territory of the Federal Republic of Germany with the exception of the territory of the former German Democratic Republic.

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	ES	Spain	MC	Monaco
AU	Australia	FI	Finland	MG	Madagascar
BB	Barbados	FR	France	ML	Mali
BE	Belgium	GA	Gabon	MR	Mauritania
BF	Burkina Fasso	GB	United Kingdom	MW	Malawi
BG	Bulgaria	GR	Greece	NL	Netherlands
BJ	Benin	HU	Hungary	NO	Norway
BR	Brazil	IT	Italy	RO	Romania
CA	Canada	JP	Japan	SD	Sudan
CF	Central African Republic	KP	Democratic People's Republic of Korea	SE	Sweden
CG	Congo	KR	Republic of Korea	SN	Senegal
CH	Switzerland	LI	Liechtenstein	SU	Soviet Union
CM	Cameroon	LK	Sri Lanka	TD	Chad
DE	Germany, Federal Republic of	LU	Luxembourg	TG	Togo
DK	Denmark			US	United States of America

Occlusion assembly for sealing openings in blood vessels
and a method for sealing openings in blood vessels.

5 The invention relates to an occlusion assembly for sealing
openings in blood vessels, comprising a spreadable occlusion ele-
ment which is to be fitted through the opening in the blood vessel
and on which a flexible retaining element passing through the wall
of the blood vessel engages, a locking element engaging on the
10 retaining element.

 An occlusion assembly of this type is disclosed in US Patent
4,744,364. In this patent it is stated that there is a possibility
for sliding a locking element over the retaining element, said
locking element then lying against the skin of the user. That is to
15 say, the force necessary to hold the occlusion element against the
wall of the blood vessel is led by the retaining element through
the outside of the wall of the blood vessel through the skin to the
outside of the skin.

 With this arrangement, as already indicated, the occlusion
20 element is located on the inside of the blood vessel. This occlusi-
on element is in general a material which dissolves in time, so
that after a few weeks the opening in the wall of the blood vessel
is sealed and no further traces of the occlusion element are found.
Because the retaining element extends both through the wall of the
25 blood vessel and the adjacent skin, it is very difficult to apply a
controlled tension thereto. After all, it is highly conceivable
that movement takes place between the blood vessel and the skin,
which will result in an uncontrolled high or low tension. In prac-
tice, however, it has been found that it is necessary to apply some
30 tension to the retaining element in order to press the occlusion
element in a guaranteed manner against the wall of the blood ves-
sel. If this tension is inadequate or is not present, there is a
risk that the occlusion element no longer performs its function
well, with the possible complication that the occlusion element no
35 longer completely seals the openings, as a result of which very
serious consequences can arise. If the tension is too high, there

is a risk of rupture or of the occlusion element being pulled through the opening in the blood vessel. This means that the occlusion assembly according to US Patent 4,744,364 is either not admissible or is admissible only in situations where it can be guaranteed that there will be no mutual movement between the wall of the blood vessel and the skin during the first few days, that is to say that the patient must remain immobile.

The aim of the present invention is to overcome this disadvantage and to provide an occlusion assembly with which it is possible to apply more tension to the retaining element.

This aim is achieved with an occlusion assembly as described above, in that the occlusion assembly comprises a fixing element, firmly connected to the retaining element, and with which the position of the fixing element on the retaining element is such that, in use, the fixing element lies in the blood vessel against the non-occluding side of the occlusion element. In contrast to the locking element according to the US specification, the locking element according to the present invention is fitted so that it lies horizontally against the wall of the blood vessel. By this means problems relating to mutual shifting of the wall of the blood vessel and the skin, with resultant tension concentrations on the retaining element, are avoided. Because it is now possible to apply greater tension to the retaining element, it can be guaranteed that the occlusion element remains in its place. In practice it has been found that there is then a risk that the occlusion element is pulled through the opening in the wall of the blood vessel. In order to avoid this, the fixing element is fitted.

According to a preferred embodiment of the invention, the fixing element is a curved-plated rod-shaped element and the retaining element is fitted in the centre thereof in such a way that when a force is applied the centre of the rod-shaped element touches the occlusion element first. In this way an even force distribution over the occlusion element is provided.

According to a further advantageous embodiment of the invention, the locking element is to be fitted movably over the retaining element against the outside of the blood vessel.

According to a further advantageous embodiment, at least one

of the occlusion element or the elements is made from bioabsorbable material. Consequently this part will disappear in time without leaving any trace. According to an advantageous embodiment, the bioabsorbable material comprises collagen or alginate. According to
5 an advantageous embodiment, the occlusion element is in sheet form and essentially circular, heart-shaped or oval. According to a further advantageous embodiment, the occlusion element contains agents which combat stenosis, such as angiotensin II-converting enzyme inhibitor.

10 The invention also relates to a method for fitting an occlusion assembly in an opening in a blood vessel, comprising the positioning of a sheath through the opening in the blood vessel, guiding an occlusion element and a retaining element, which is coupled therewith, through said sheath into the blood vessel,
15 removing the sheath from the opening in the blood vessel and then placing a locking element on the retaining element. A method of this type is disclosed in US-A-4,744,364. As already indicated above, with this method the locking element is placed horizontally against the skin. It has likewise been stated that this has the
20 disadvantage that it is not possible with this arrangement to guarantee that the tension on the retaining element with which the occlusion element is pressed against the wall of the blood vessel is always sufficient.

The aim of the present method is to provide means of overco-
25 ming this disadvantage. This aim is achieved in that the locking element is fitted horizontally against the outside of the blood vessel. By this means effects of mutual movement between the wall of the blood vessel and the skin and any living tissue between the two are avoided. According to an advantageous embodiment of this
30 method, the retaining element is connected to a fixing element, which is inserted in the sheath before the occlusion element.

The invention is illustrated in more detail below with reference to the illustrative embodiments shown in the drawing. In the drawing:

35 Fig. 1 shows a side view of a first embodiment of the occlusion assembly according to the invention;

Fig. 2 shows a top view of the same embodiment;

Fig. 3 shows the fitting of the occlusion assembly according to Fig. 1 and 2 in a blood vessel;

Fig. 4 shows the occlusion assembly according to the above embodiment fitted in a blood vessel;

5 Fig. 5a, b, c show a top view of further embodiments of the occlusion assembly according to the invention;

Fig. 6 shows a further embodiment of the occlusion assembly according to the invention fitted in a blood vessel;

10 Fig. 7 shows a side view of a further embodiment of the occlusion assembly according to the invention fitted in a blood vessel.

A side view of a first embodiment of the occlusion assembly according to the invention is shown in Fig. 1. This comprises a flexible sheet 1 as occlusion element and a retaining element 2, 15 which in this case is in the form of a thread, connected to the centre of said occlusion element. A top view of the various features is drawn in Fig. 2.

Fig. 3 shows a blood vessel 8 in which a sheath 6, known for any medical application, has been inserted. After removing the 20 sheath 6, the problem up to now has been that an appreciable opening was formed in the blood vessel which had to be sealed in some way. The means of sealing described in the prior art were found to be unreliable or to impose restrictions in movement on the patient. According to the invention, the assembly shown in Fig. 1 and 2 is 25 inserted through the sheath, as shown. After the occlusion element 1 has been fitted in the blood vessel 8, the unfoldable sheet 1 unfolds in such a way that the surface area thereof is larger than the surface area of the opening to be occluded. Sheath 6 is then moved out of the opening, as a result of which the latter will 30 become somewhat smaller. By pulling on the retaining thread, sheet 1 will come to lie against blood vessel 8 in the manner shown in Fig. 4. By making both the sheet 1 and retaining element 2 of bioabsorbable material, it is ensured that after the opening in the blood vessel has occluded these parts will disappear, for example 35 after a few weeks.

Various other embodiments of the flexible occlusion element or plug 1 are shown in Fig. 5a, b, c. Depending on the possibili-

ties for insertion through the sheath and the opening made in the blood vessel, these can be used.

5 A further embodiment of the occlusion assembly according to the invention is shown in Fig. 6. This essentially corresponds to the occlusion assembly described with reference to the above figures, except that a retainer ring 10 is fitted over the fixing thread. This retainer ring 10 or locking element serves for accurate determination of the position of occlusion element 1 and is likewise made of a biologically absorbable material. The ring 10
10 has an internal diameter such that, on the one hand, it can slide in a supple manner over retaining element 2 but, on the other hand, provides some mutual clamping force on these two parts. In contrast to the prior art, the locking element 10 lies against the outside of the blood vessel 8. Consequently, there is tension in the retaining thread only in the part which must bridge the wall thickness
15 of the blood vessel.

A further embodiment of the invention is shown in Fig. 7. The same reference numerals as in the preceding figures have been used for corresponding parts in this figure. In contrast to the earlier
20 embodiments, the retaining thread 2 is now attached to a fixing element 12 which in this case consists of a rod-shaped curved-plated part. The occlusion element, indicated by 13, is provided with an opening 14 located in the centre, through which the retaining element 2 passes. As a result of the use of the fixing element
25 12, the tension in the retaining thread 2 can be increased, by which means it is guaranteed that the occlusion element 13 remains in its place. With this arrangement, because of the greater strength of the fixing element, pulling of the occlusion element through the opening in the blood vessel is prevented. The fixing element,
30 as well as the occlusion element and the locking element, can be made of a biocompatible material. The occlusion element can contain angiotensin II-converting enzyme inhibitor, an agent which combats constriction of the blood vessels.

It must be understood that the embodiments described above
35 are merely examples and that the invention is not restricted to these. Thus, the fixing element can comprise all means known in the prior art and is not restricted to the thread shown in the drawing.

Likewise, the unfoldable element to be inserted in the blood vessel can comprise all possible imaginable configurations.

The invention also relates to the use of bioabsorbable material for the production of an occlusion means for sealing puncture holes in blood vessels, as described above.

The outstanding functioning/characteristics of the occlusion means according to the invention are illustrated with reference to results of in vitro and in vivo tests, which are described below.

IN VITRO TESTS

10 Aim:

Testing occluder with regard to:

- 1 strength of fixing thread/plug connection immediately after insertion and after 1 hour
- 2 pressure resistance of occluder, acute and after 1 hour
- 15 3 "blood tightness", acute and after 1 hour
- 4 effectiveness of occluder in the case of movements
- 5 effectiveness of occluder for insertion openings of different diameter

20 In order to have a criterion for effectiveness, the occlusion frequency is determined with regard to the insertion frequency (ratio of number of effective occlusions to number of times occluder inserted)

- 6 unfolding of plug
- 7 flow pattern of fluid and pressure drop around occluder
- 25 (turbulence)
- 8 embolization frequency

Test set-up:

All tests are carried out with heparinized fresh blood. The following blood parameters are known:

- 30 - haemoglobin content (Hb)
- haematocrit (Ht)
- platelet content
- thrombotest (TT)
- cephalin time

35 Test set-up for tests 1 to 5 inclusive:

An artery from a test animal (dog, pig) with a diameter of about 7 mm is central in the set-up. This artery is occluded at

both ends, on one side by means of a clamp and on the other side by means of a valve. Via this valve the lumen of the artery is connected to a bag of blood which is placed in a pressure bag. The pressure in the blood vessel is kept constant at 150 mm Hg. A sheath
5 with a standard internal diameter of 9 French (2.9 mm) is inserted in the artery by means of the customary technique. The maximum diameter of the plug is standard 4.0 mm.

The insertion module is such that this can be inserted through a standard sheath with an internal cross-section of 5 French
10 (1.65 mm).

The following experiments are carried out in this set-up:

1. Strength of fixing thread/plug connection immediately after insertion and after 1 hour

Aim: testing the strength of the fixing thread, the connection between fixing thread and plug and the deformability of the plug under the influence of a force exerted from outside.
15 Method: this is tested by hanging a weight of 250 gram on the fixing thread for 15 minutes.

2. Pressure resistance of occluder, acute and after 1 hour

Aim: testing the mechanical strength and deformability of the plug under the influence of a force from inside.
20 Method: this is tested by increasing the pressure in the blood vessel to 300 mm Hg for 15 minutes.

3. "Blood tightness", acute and after 1 hour

Aim: testing the amount of blood which passes through the plug and the insertion hole although the plug is mechanically well positioned.
25

Method: this measurement is combined with experiment 2. The amount of blood which has diffused through the plug is measured by collecting this blood on dry gauzes and weighing the gauzes before and after the experiment. The difference in weight in grams is regarded as the amount of diffused blood in ml.
30

4. Effectiveness of occluder in the case of movements

Aim: testing the stability of the plug when the blood vessel moves.
35

Method: the vessel is fixed at one end and suspended at the

other end on an oscillating rod. This rod is moved by an electric motor with a frequency of 1 Hz. A small rod is positioned transversely over the vessel, at about 2 cm from the puncture site, in such a way that said small rod acts as a hinge point for the vessel. The positioning of the vessel is such that the section connected to the rod describes a segment of a circle between 0 and 150°. The puncture site is in the moving part of the vessel. The test time is 30 minutes.

- 5
10 5. Effectiveness of occluder for insertion openings of different diameter.

Aim: testing the effectiveness of the occluder for insertion openings of different diameter.

- 15 Method: the standard plug with a cross-section of 4 mm is inserted after puncture sites have been made with the following internal sheath diameters: 5 French (1.65 mm), 7 French (2.3 mm) and 9 French (2.9 mm). These tests are carried out under standard conditions and are evaluated using the occlusion/insertion ratio (O/I ratio, 100% success = 1, 0% success = 0).
- 20

Test set-up for tests 6 to 8 inclusive:

- 25 An artery originating from a test animal (dog, pig) with a cross-section of about 7 mm is central in the set-up. The set-up further consists of a roller pump, a heat exchanger, a pressure vessel, a haemofilter and a collection vessel. The blood is pumped from the collection vessel (= atmospheric pressure) by the roller pump into the pressure vessel. The pressure vessel is partially filled with air. An adjustable valve, by means of which the fluid can be kept under pressure, is in the top of the pressure vessel.
- 30 Any air bubbles entrained in the blood pumped from the collection vessel can be removed in the pressure vessel. From the pressure vessel, the blood flows to the artery via a heat exchanger. Two pressure lines (upstream and downstream of the plug) and a temperature measuring point are fitted in the artery. Downstream of
- 35 the vessel there is a haemofilter and an adjustable resistance. During the experiment the temperature is kept at 37°C and the pressure upstream of the plug at 150 mm Hg. Flow can be measured

after passage of the blood through the haemofilter downstream of the vessel downstream of the resistance, before the blood flows back into the collection vessel, by means of a graduated beaker and a chronometer.

5 If necessary, the vessel is supported on the outside by a (plastic) tube to simulate the tissue pressure. The position of the insertion opening is left exposed in this case. For evaluation of flow speeds and flow patterns around the plug use can be made of a standard colour Doppler Echo apparatus.

10 The following experiments are carried out in this set-up:

6. Unfolding of plug

Aim: testing to determine whether the plug unfolds as expected.

15 Method: it is attempted to visualize the plug by means of echography and to determine the shape.

7. Flow pattern of fluid and pressure drop around occluder (turbulence)

Aim: testing to establish that the plug does not cause stenoses.

20 Method: after initial measurements of pressure and flow, the plug is inserted. After insertion of the plug these measurements are repeated to determine whether the plug has a stenosing action. The flow pattern around the plug is also visualized with the aid of colour Doppler Echo.

25 8. Embolization frequency

Aim: testing to establish that the plug does not act as an embolization source.

30 Method: after each insertion of the plug, blood is circulated for 2 hours. The haemofilter is then checked and replaced. The pores of the haemofilter are the same size as those of filters used in extracorporeal circulation. The number, the size and, where possible, the composition of the emboli are documented.

35 Tests 6, 7 and 8 can be carried out simultaneously. Tests 6 and 7 are carried out both at the start and just before the end of the experiments.

IN VIVO TESTS

In the case of in vivo tests the following points are of importance:

- stability of plug
- haemorrhaging rate at the site of the puncture hole
- 5 - effect of rapid mobilization on stability of the plug
- vessel recovery at the puncture site
- formation of aneurysms at the puncture site
- frequency of stenosis at the site of the plug
- absorption of plug and fixing thread with time
- 10 - scarring around plug and fixing thread
- thrombogenicity of plug
- frequency of embolization of plug material
- occurrence of infections at the site of the plug
- toxicity of plug and fixing thread

- 15 The test animal is an animal of adequate size (dog, pig). After adequate anaesthesia and connection for artificial respiration, a catheter is inserted in the a. carotis for pressure registration. Heparinization is effected by intravenous administration of 100 U/kg of body weight. Blood is taken to
- 20 determine haemoglobin (Hb), haematocrit (Ht), platelets, thrombotest (TT) and cephalin time.

- A blood vessel of adequate diameter is sought (a. iliaca, aorta). Via a catheter in the a. carotis, an initial angiogram is made of the blood vessel to be punctured. A standard 9 French
- 25 sheath is inserted, followed by the insertion of the standard plug (diameter 4 mm).

- Depending on the size of the selected blood vessel, one or more puncture sites may be made. After inserting the plug, there is a 15 minute period of observation to determine whether the plug
- 30 remains stable in place and whether there is any "oozing" at the puncture site (semi-quantitative assessment). After the procedure, a check angiography of the punctured vessel segment is made before removing the sheath from the a. carotis. In the event of survival, blood is taken the following day to determine Hb and Ht. A clinical
- 35 evaluation is also carried out to determine whether there are any emboli. Before termination, a check angiography is made of the punctured vessel segment. After termination, the puncture site is

sought and removed and fixed in formalin (for light microscopy) or glutaraldehyde (for scanning electron microscopy, SEM).

Survival periods in days: 0, 1, 7, 30, 90, 180.

- 5 A control group consists of test animals which undergo the same procedure except for the arterial puncture.

The results of both the in vivo and in vitro tests indicate that the occlusion means according to the invention is outstandingly suitable for the intended application.

CLAIMS

1. An occlusion assembly for sealing openings in blood vessels, comprising a spreadable occlusion element which is to be fitted through the opening in the blood vessel and on which a flexible retaining element passing through the wall of the blood vessel engages, a locking element engaging on the retaining element, characterized in that the occlusion assembly comprises a fixing element, firmly connected to the retaining element, and with which the position of the fixing element on the retaining element is such that, in use, the fixing element lies in the blood vessel against the non-occluding side of the occlusion element.
2. Occlusion assembly according to Claim 1, wherein the fixing element comprises a curved-plated rod-shaped element and the retaining element is fitted in the centre thereof in such a way that when a force is applied the centre of the rod-shaped element touches the occlusion element first.
3. Occlusion assembly according to one of the preceding claims, wherein the locking element is movable along the retaining element in order to lie against the outside of the blood vessel.
4. Occlusion assembly according to one of the preceding claims, wherein at least one of the occlusion element or the elements consists of bioabsorbable material.
5. Occlusion assembly according to Claim 4, wherein the bioabsorbable material comprises collagen or alginate.
6. Occlusion assembly according to one of the preceding claims, wherein the occlusion element is in sheet form and has an essentially circular, heart-shaped or oval shape.
7. Occlusion assembly according to one of the preceding claims, wherein the occlusion element contains agents combating stenoses.
8. Method for fitting an occlusion assembly in an opening in a blood vessel, comprising the positioning of a sheath through the opening in the blood vessel, guiding an occlusion element and a retaining element, which is coupled therewith, through said sheath into the blood vessel, removing the sheath from the opening in the blood vessel and then placing a locking element on the retaining element, characterized in that the locking element is fitted to lie horizontally against the outside of the blood vessel.

9. Method according to Claim 8, wherein the retaining element is connected to a fixing element, which is inserted in the sheath before the occlusion element.

1/3

fig -1




fig -2





fig -3



2/3

fig - 4




fig - 5a




fig - 5b




fig - 5c




fig - 6








fig - 7



INTERNATIONAL SEARCH REPORT

International Application No PCT/NL 90/00078

I. CLASSIFICATION OF SUBJECT MATTER (if several classification symbols apply, indicate all) ⁶ According to International Patent Classification (IPC) or to both National Classification and IPC IPC ⁵ : A 61 B 17/12								
II. FIELDS SEARCHED <div style="text-align: center; border-top: 1px solid black; border-bottom: 1px solid black; margin: 5px 0;">Minimum Documentation Searched ⁷</div> <table style="width: 100%; border-collapse: collapse;"> <tr> <th style="width: 30%; border-bottom: 1px solid black;">Classification System</th> <th style="border-bottom: 1px solid black;">Classification Symbols</th> </tr> <tr> <td style="border-right: 1px solid black; padding: 5px;">IPC⁵</td> <td style="padding: 5px;">A 61 B</td> </tr> </table> <div style="border-top: 1px solid black; padding-top: 5px; margin-top: 5px;"> Documentation Searched other than Minimum Documentation to the Extent that such Documents are Included in the Fields Searched ⁸ </div>			Classification System	Classification Symbols	IPC ⁵	A 61 B		
Classification System	Classification Symbols							
IPC ⁵	A 61 B							
III. DOCUMENTS CONSIDERED TO BE RELEVANT ⁹ <table style="width: 100%; border-collapse: collapse;"> <tr> <th style="width: 10%; border-bottom: 1px solid black;">Category ⁹</th> <th style="border-bottom: 1px solid black;">Citation of Document, ¹¹ with indication, where appropriate, of the relevant passages ¹²</th> <th style="width: 10%; border-bottom: 1px solid black;">Relevant to Claim No. ¹³</th> </tr> <tr> <td style="border-right: 1px solid black; vertical-align: top; padding: 5px;">A</td> <td style="border-right: 1px solid black; padding: 5px;"> US, A, 4744364 (KENSEY) 17 May 1988 see column 3, line 66 - column 4, line 9; column 4, lines 26-30; column 5, lines 28-34; figure 4 (cited in the application) <div style="text-align: center;">-----</div> </td> <td style="vertical-align: top; padding: 5px;">1,8</td> </tr> </table>			Category ⁹	Citation of Document, ¹¹ with indication, where appropriate, of the relevant passages ¹²	Relevant to Claim No. ¹³	A	US, A, 4744364 (KENSEY) 17 May 1988 see column 3, line 66 - column 4, line 9; column 4, lines 26-30; column 5, lines 28-34; figure 4 (cited in the application) <div style="text-align: center;">-----</div>	1,8
Category ⁹	Citation of Document, ¹¹ with indication, where appropriate, of the relevant passages ¹²	Relevant to Claim No. ¹³						
A	US, A, 4744364 (KENSEY) 17 May 1988 see column 3, line 66 - column 4, line 9; column 4, lines 26-30; column 5, lines 28-34; figure 4 (cited in the application) <div style="text-align: center;">-----</div>	1,8						
<div style="display: flex; justify-content: space-between;"> <div style="width: 45%;"> <p>⁹ Special categories of cited documents: ¹⁰</p> <p>"A" document defining the general state of the art which is not considered to be of particular relevance</p> <p>"E" earlier document but published on or after the international filing date</p> <p>"L" document which may throw doubt on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)</p> <p>"O" document referring to an oral disclosure, use, exhibition or other means</p> <p>"P" document published prior to the international filing date but later than the priority date claimed</p> </div> <div style="width: 45%;"> <p>"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention</p> <p>"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step</p> <p>"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.</p> <p>"A" document member of the same patent family</p> </div> </div>								
IV. CERTIFICATION <table style="width: 100%; border-collapse: collapse;"> <tr> <td style="width: 50%; border-bottom: 1px solid black; padding: 5px;"> Date of the Actual Completion of the International Search <div style="text-align: center;">27th September 1990</div> </td> <td style="width: 50%; border-bottom: 1px solid black; padding: 5px;"> Date of Mailing of this International Search Report <div style="text-align: center;">15. 10. 90</div> </td> </tr> <tr> <td style="border-bottom: 1px solid black; padding: 5px;"> International Searching Authority <div style="text-align: center;">EUROPEAN PATENT OFFICE</div> </td> <td style="border-bottom: 1px solid black; padding: 5px;"> Signature of Authorized Officer <div style="text-align: center;">  H. Ballsteros </div> </td> </tr> </table>			Date of the Actual Completion of the International Search <div style="text-align: center;">27th September 1990</div>	Date of Mailing of this International Search Report <div style="text-align: center;">15. 10. 90</div>	International Searching Authority <div style="text-align: center;">EUROPEAN PATENT OFFICE</div>	Signature of Authorized Officer <div style="text-align: center;">  H. Ballsteros </div>		
Date of the Actual Completion of the International Search <div style="text-align: center;">27th September 1990</div>	Date of Mailing of this International Search Report <div style="text-align: center;">15. 10. 90</div>							
International Searching Authority <div style="text-align: center;">EUROPEAN PATENT OFFICE</div>	Signature of Authorized Officer <div style="text-align: center;">  H. Ballsteros </div>							

NL 9000078
SA 37659

EPO FORM P0479

For more details about this annex : see Official Journal of the European Patent Office, No. 12/82